Cohance Lifesciences Ltd Q1 FY27 Earnings Call: Confirms Q1 as Trough, Defers $1B Target

Cohance Lifesciences Ltd held its Q1 FY27 earnings call on August 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Trough quarter with sharp revenue decline and margin compression

• Consolidated revenue declined 23% YoY to $223M in Q1 FY 2026-2027, driven by shipment phasing in pharma CDMO, softer agrochemicals, and low formulation revenue.
• Consolidated adjusted EBITDA margin fell to 2.2% ($92M), reflecting lower revenue, negative operating leverage, and subsidiary consolidation in Q1 FY 2026-2027.
• Standalone business (ex-subsidiaries) showed relative strength — revenue of $3,599M and adjusted EBITDA margin of 9.2% ($332M) in Q1 FY 2026-2027.
• NJ Bio recorded an adjusted EBITDA loss of $328M on revenue of $350M; management expects losses to continue weighing on consolidated profitability in the near term.
• Management confirmed Q1 FY 2026-2027 was the trough — improvement expected in Q2 and a return to YoY growth from H2 FY 2026-2027.
• Capital expenditure for Q1 FY 2026-2027 was $598M; consolidated net cash stood at $2,512M as of Jun 30, 2026.

Pharma CDMO drags; API Plus holds up; Specialty Chemicals transitions

• Pharma CDMO revenue declined 38.7% YoY in Q1 FY 2026-2027 due to customer shipment phasing, with some deliveries shifted into Q2. Commercial vs. development split was 57%/43%.
• API Plus performed slightly ahead of internal expectations in Q1 FY 2026-2027, aided by favorable pricing and improved product mix; its revenue mix rose to 60% of segment revenue.
• Formulation business was slightly below expectations in Q1 FY 2026-2027, impacted by an API production delay, lower demand for a mature product, and a customer-led pack configuration change.
• Specialty chemicals declined 34.7% YoY in Q1 FY 2026-2027, driven by H2-dominated phasing in Actem CDMO, though performance materials delivered growth.
• Sapala (oligonucleotide segment) grew 2.5x YoY to $274M in Q1 FY 2026-2027 with strong margins, benefiting from supply under a specialized nucleic acid building block program.
• API Plus price increases in Q1 FY 2026-2027 were driven by raw material cost escalations due to the geopolitical situation; a "major chunk" of cost escalation was passed on to customers.

Late-stage pipeline and restocking orders support medium-term recovery

• Small molecule CDMO holds a late-stage pipeline of 10 phase 3 assets; management expressed confidence in recovery based on anchor relationships with 2–3 customers built over 7 years.
• Two molecules entered commercial supply in Q1 FY 2026-2027; a restocking order for a previously destocked commercial molecule provides delivery visibility for Q4 FY 2026-2027 and FY 2027-2028.
• ADC payload business added MMAE and Exatecan to the portfolio; NJ Bio released another GMP ADC batch and operationalized an additional GMP lab at Princeton.
• API Plus secured 2 CEP approvals and filed 2 Korean DMFs in Q1 FY 2026-2027; management targets 7 new API filings in FY 2026-2027.
• Formulation business targets approximately 10 product launches in FY 2026-2027, including 2 launches planned for Q2 FY 2026-2027, supported by a finalized supply agreement for Middle Eastern markets.
• Specialty chemicals: a confirmed active ingredient program with an existing global innovator entered the registration process in Q1; the first qualification campaign with 2 Japanese innovators is scheduled in FY 2026-2027.

Operating deleverage persists; NJ Bio remains a drag on consolidated profitability

• Q1 FY 2026-2027 standalone EBITDA margins of 9% reflected significant operating deleverage due to low revenue; management expects margins to "steadily increase year-on-year" as top line grows, but noted it is difficult to articulate if margins will return to the historical level of 35%.
• CFO Himanshu Agarwal guided FY 2026-2027 EBITDA margin to be "closer to previous year margin percentage," with acceleration expected from FY 2027-2028 onwards.
• NJ Bio's losses expected to continue weighing on consolidated profitability until revenue conversion improves; management's near-term objective is to make the cost base commensurate with revenue.
• Cost optimization is focused on assets not creating value (low-utilization capacity, US ADC costs) by generating more revenue/utilization rather than cutting spending.
• Other expenses in Q1 FY 2026-2027 contained no merger-related one-offs; management expects other expenses to remain at similar levels through FY 2026-2027, reflecting continued operating deleverage at lower revenue.
• API Plus price increases in Q1 FY 2026-2027 were driven by raw material cost escalations due to the geopolitical situation; a "major chunk" of the cost escalation was passed on to customers.

USFDA cites Pashamylaram; quality metrics otherwise robust

• USFDA completed an inspection of the Pashamylaram facility (Jul 27–Aug 5, 2026) and issued a Form 483 with five observations; management stated none relate to data integrity and will respond within stipulated timelines.
• Multiple audits by large innovator partners during Q1 FY 2026-2027 were completed without critical findings; commercial on-time execution (OTE) remained at nearly 100%.
• Management reported achieving EcoVadis Gold, strong CDP ratings, SBTi validation, and ISO 22301 certification during the quarter.
• At Nacharam, remediation and operational stabilization remain the immediate priority; Kappa implementation is on track with ongoing regulator engagement and product supplies have resumed.
• Commercial OTIF (On Time In Full) was 100% YTD in Q1 FY 2026-2027; a new effluent treatment facility at Ankleshwar was commissioned and de-bottlenecking initiatives for several products were completed.
• Management announced integration of nucleic acid (oligo) capabilities into one unit, with Dr. P.Y. Reddy leading through FY30 and a "clear path to full ownership of Sepala by FY30."

H2 recovery expected; $1B target deferred; medium-term drivers intact

• Management declined to reaffirm the $1 billion sales target for FY 2029-2030, calling it an "aspiration" and promising an update by December 2026.
• Sequential growth expected in Q2 FY 2026-2027, with improving momentum through H2 FY 2026-2027 and a return to YoY growth from H2; Q2 is anticipated to be "significantly better" than Q1.
• API Plus medium-term outlook calls for sustainable double-digit growth, supported by a robust API order book, strong development pipeline, and management's estimate that current size/scale is only 30–40% of potential "over a 3–5 year horizon."
• Specialty chemicals guidance: FY 2026-2027 will be a "year of qualification" to support the base against generic pressure; from FY 2027-2028 onwards, management believes the portfolio can support sustained double-digit growth.
• Oligonucleotide CDMO identified as a significant growth driver with a "solid chance of nearly doubling in 3-4 years" and growing "significantly faster," according to management.
• Rs.260 crores destocking impact from the prior year — one molecule has resumed with orders spread over two years (FY 2026-2027 and FY 2027-2028); clarity on the remaining restocking split is expected by end of Q2 FY 2026-2027.